CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study
(2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2022). CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study. Value in Health, 25(7, Supplement), Page S305. https://doi.org/10.1016/j.jval.2022.04.105
All Outputs (7)
POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis (2022)
Conference Proceeding
Robson, J., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Ndosi, M. (2022). POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis. . https://doi.org/10.1136/annrheumdis-2022-eular.1769Background Giant cell arteritis (GCA) is caused by inflammation of the blood vessels of the head and neck; patients can present with cranial, ocular or large vessel vasculitis involvement. Treatment is with glucocorticoids, steroid sparing agents a... Read More about POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis.
P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Journal Article
Almeida, C., Guly, C., Mackie, S., Bromhead, A., Stern, S., Dures, E., …Robson, J. C. (2022). P301 Patient reported outcome measure for giant cell arteritis: Clinical testing. Rheumatology, 61(Supplement_1), Article keac133.300. https://doi.org/10.1093/rheumatology/keac133.300Background/Aims Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.
OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. C. (2022). OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study. Rheumatology, 61(Supplement_1), https://doi.org/10.1093/rheumatology/keac132.023
Development and validation of a patient reported outcome measure for giant cell arteritis (2021)
Presentation / Conference
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2021, November). Development and validation of a patient reported outcome measure for giant cell arteritis. Poster presented at ACR Convergence 2021, Online
Patient perceptions of physical activity after a diagnosis of giant cell arteritis: Analysis of multinational qualitative data (2021)
Journal Article
Austin, K., Dures, E., Almeida, C., Cramp, F., Guly, C. M., Hill, C. L., …Robson, J. C. (2022). Patient perceptions of physical activity after a diagnosis of giant cell arteritis: Analysis of multinational qualitative data. Arthritis Care and Research, 74(1), 99-106. https://doi.org/10.1002/acr.24800Objective: To explore patient perceptions of physical activity in giant cell arteritis (GCA). Methods: This was a multinational qualitative study, analyzing interview data collected from participants from the UK (n=25) and Australia (n=11) with a def... Read More about Patient perceptions of physical activity after a diagnosis of giant cell arteritis: Analysis of multinational qualitative data.
Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure (2021)
Journal Article
Robson, J. C., Almeida, C., Dawson, J., Bromhead, A., Dures, E., Guly, C., …Hill, C. (2021). Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure. Rheumatology, 60(10), 4671-4680. https://doi.org/10.1093/rheumatology/keab076Objectives: GCA is a large vessel vasculitis (LVV) presenting with headache, jaw claudication, musculoskeletal and visual involvement. Current treatment is glucocorticoids and anti-IL-6 tocilizumab in refractory disease. The objective of this study w... Read More about Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure.